Research Article

MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy

Table 3

Multivariate analysis of predictors associated with PCa and csPCa.

VariablePCacsPCa
OR95% CIp valueAUCOR95% CIp valueAUC

Nomograms0.83-0.92< 0.0010.8780.87-0.96< 0.0010.927
Age, yr1.091.03-1.160.0051.081.00-1.160.028
PSA, ng/ml1.061.03-1.100.0011.071.03-1.120.001
f/t, %0.8280.574
PV, ml0.970.96-0.98< 0.0010.970.95-0.99< 0.001
PSAD, ng/ml/ml0.1380.421
PSAV, ng/ml/yr0.5250.406
DRE3.21.08-9.410.0354.371.39-13.800.012
TRUS0.2000.245
mpMRI
 Negative11
 Suspicious3.271.12-9.520.0304.781.47-15.520.009
 Positive5.822.34-14.46< 0.0018.413.14-22.50< 0.001

PCa, prostate cancer; csPCa, clinically significant prostate cancer; OR, Odds Ratio; CI, confidence interval; AUC, area under the receiver operating characteristics curve; PSA, prostate-specific antigen; f/t, free/total PSA ratio; PV, prostate volume; PSAD, PSA density; PSAV, PSA velocity; DRE, digital rectal examination; TRUS, transrectal ultrasound; mpMRI, multi-parametric magnetic resonance imaging.